Holographic Technology Expands its Application Possibilities: CES 2020

 

On day one of CES 2020, Daniel Litwin, the Voice of B2B, checked in with Andy Travers, CEO, Ceres Holographics, to learn more about the innovative solutions and business opportunities hologram technology provides. Travers began his journey with Ceres focused on the commercial side of holographic technology, and preparing this technology for new markets, i.e., the transportation industry. Ceres design an adaptable, holographic process for use in the cars of today and tomorrow.

The evolving technology from the traditional surface relief hologram, used in credit cards, to volume holography allows for a wide range of display applications, like automobile windscreens, because it removes the rainbow effect. While Ceres’ primary focus is on holographic technology, they realized the importance of system design as well. “Our team is not just holographers. We’ve got system optical designers, computational people,” said Travers. “we’re even extending our resources to do the content, because with the content you need to know how the hologram and the system works so you know what content you can generate, in real-time, when you’re driving a car.”

Two types of holographic display technologies in use now are transparent displays, built into the car windshield, and augmented reality HUDs. Transparent displays can reduce dashboard clutter and be used with side mirrors as well. Augmented reality HUDs have an extended projection range with a multitude of potential information and advertising capabilities. Travers said as the demand for smartphone use in automobiles increases, the need for holographic technology to display that information will make it a ‘must-have’ for consumers.

For the latest news, videos, and podcasts in the Software & Technology Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!
Twitter – @TechMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More